9,189 Shares in Oruka Therapeutics, Inc. $ORKA Bought by ProShare Advisors LLC

ProShare Advisors LLC bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 4th quarter, Holdings Channel reports. The fund bought 9,189 shares of the company’s stock, valued at approximately $279,000.

Several other institutional investors have also recently bought and sold shares of the company. Fairmount Funds Management LLC raised its holdings in Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the period. Viking Global Investors LP bought a new position in Oruka Therapeutics in the 3rd quarter worth $51,280,000. Deep Track Capital LP raised its holdings in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the period. Vanguard Group Inc. raised its holdings in Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after acquiring an additional 676,865 shares during the period. Finally, Commodore Capital LP raised its holdings in Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after acquiring an additional 333,340 shares during the period. Institutional investors own 56.44% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Stifel Nicolaus lifted their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, April 30th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a report on Monday, April 27th. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, May 18th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $120.80.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the sale, the insider owned 33,377 shares of the company’s stock, valued at $2,064,367.45. The trade was a 17.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 139,055 shares of company stock worth $8,095,785. Insiders own 23.49% of the company’s stock.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $58.53 on Monday. The stock has a market cap of $3.53 billion, a P/E ratio of -30.17 and a beta of -0.25. The company’s 50-day simple moving average is $59.69 and its 200 day simple moving average is $41.63. Oruka Therapeutics, Inc. has a twelve month low of $10.64 and a twelve month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.05 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.